MedWatch

Novo CEO dismisses price pressure on growing GLP-1 segment

Although Victoza yielded disappointing results in first quarter, and Novo Nordisk's GLP-1 portfolio is generally under pressure, CEO Lars Fruergaard Jørgensen denies that the segment is subject to increased competition or price pressure. The company has no influence on the underlying reasons, he says.

Foto: Ritzau Scanpix/ERH/Niels Hougaard

Most sales figures surprised positively when Danish drug group Novo Nordisk presented the first interim report for 2019 last week.

One product, however, could not keep up with the positive development - the company's best-seller Victoza for treatment of type 2 diabetes. In first quarter of 2019, Victoza generated DKK 5.7 billion (USD 860 million) relative to the analysts' estimate of DKK 6 billion or more.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier